The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Incyte
Stock and Other Ownership Interests - Incyte
Longitudinal evaluation of quality of life (QoL) in patients (Pts) with FGFR2-driven cholangiocarcinoma (CCA) treated with pemigatinib.
 
Juan W. Valle
Consulting or Advisory Role - Agios; AstraZeneca; Delcath Systems; GenoScience Pharma; Incyte; Ipsen; Keocyt; Merck; Mundipharma; Novartis; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; Wren Laboratories
Speakers' Bureau - Imaging Equipment Limited; Ipsen; Novartis; Nucana
Travel, Accommodations, Expenses - Celgene; Nucana
 
Kristen Bibeau
No Relationships to Disclose
 
Yohan Cho
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Haobo Ren
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Luis Féliz
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Christine Francis Lihou
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene; CytomX Therapeutics (I); Eisai; Flatiron Health; Genoscience Pharma; Gilead Sciences; Gilead Sciences; Incyte; Ipsen; LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; QED Therapeutics; RedHill Biopharma; Roche/Genentech; Silenseed (I); Sillajen; SOBI (I); TheraBionic; twoXAR; Vector Health; Yiviva
Research Funding - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Exelixis (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris